Resultados de la búsqueda 71-80 de 3702 para anti-TNF drugs

  1. Neurología - Ensayos clínicos - Mayo Clinic

    Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment. Submandibular Gland ...

  2. Neurología - Ensayos clínicos - Mayo Clinic

    Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous ...

  3. Neurología - Ensayos clínicos - Mayo Clinic

    Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous ...

  4. Neurología - Ensayos clínicos - Mayo Clinic

    Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous ...

  5. Untitled

    Page 1.

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... drug resistance/response profile will be a major focus of this aim. The second aim is to conduct high-throughput testing of various drugs (e.g., virotherapy ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... drug resistance/response profile will be a major focus of this aim. The second aim is to conduct high-throughput testing of various drugs (e.g., virotherapy ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... drug resistance/response profile will be a major focus of this aim. The second aim is to conduct high-throughput testing of various drugs (e.g., virotherapy ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to test drug enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) ...

  10. Neurología - Ensayos clínicos - Mayo Clinic

    Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous ...